Objective: To estimate the prevalence of the use of cancer risk‐reducing measures among
Australian BRCA1 and BRCA2 mutation carriers. Design, setting and participants …

In nanocatalytic medicine, drugs can be transformed into toxic components through highly
selective and highly specific catalytic reactions in the tumor microenvironment, avoiding …

Women with pathogenic BRCA genetic mutations face high risks for cancer development.
Estimates vary among mutation carriers, with lifetime risks ranging from 41% to 90% for …

For over two decades, scholars in the humanities and social sciences have attended warily
and thoughtfully to the growing influence of biological and especially genetics‐based …

Background The rate of risk-reducing bilateral mastectomy (RRBM) among cancer-free
Israeli female BRCA1/BRCA2 mutation carriers was reportedly 13% in 2010. Current RRBM …

Objectives: Genetic mutations in breast cancer susceptibility genes BRCA1/2 are associated
with an increased risk of breast/ovarian cancers. Cost‐effective preventive measures are …

Familial cancer services have been developed in many countries in response to a rapidly
evolving demand for genetic counseling and testing for breast cancer risk. This article …

The purpose of this study is to determine the prevalence and predictors of contralateral risk-
reducing mastectomy (CRRM) in Australasian women at high familial risk of a second …

Background Women with a BRCA1 or BRCA2 genetic mutation have several options for
cancer prevention, including prophylactic surgery, chemoprevention and screening. In this …

Background: The knowledge about and use of chemopreventive agents for prostate cancer
by physicians has not been described. The Prostate Cancer Prevention Trial (PCPT) …